Description
The dysfunction of the skin barrier is one of the main pathomechanisms in canine atopic dermatitis (CAD). Restoration of its functionality must be part of any treatment for CAD. Several in vivo and in vitro studies have demonstrated the efficacy of topical application of sphingolipids.
